AMEERA-5: A Randomized, Double-Blind Phase III Study of Amcenestrant + Palbociclib vs Letrozole + Palbociclib for Previously Untreated ER+/HER2- Advanced Breast Cancer

home / investigator-perspectives / ameera-5-a-randomized-double-blind-phase-iii-study-of-amcenestrant-palbociclib-vs-letrozole-palb

Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.